Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 20,623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Phase 1Phase 2 Interventional Results available

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

NCT00452374
View directory record Official record
Conditions
Leukemia
Interventions
Cytarabine, Fludarabine, Oxaliplatin, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
La Jolla, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT04014790
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease, Prevention of aGVHD
Interventions
RGI-2001, Standard of Care
Drug
Lead sponsor
Regimmune Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Phase 2 Interventional

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

NCT03913559
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Results available

Telehealth Delivery (Tele-B6)

NCT05829759
View directory record Official record
Conditions
HIV Seropositivity, Bisexuality
Interventions
Tele-B6, Delayed intervention (waitlist control)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Withdrawn Not applicable Interventional

Smartphone-facilitated Asthma Control

NCT02205723
View directory record Official record
Conditions
Childhood Asthma
Interventions
Asthma teaching in ER, Smartphone Asthma Control
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
4 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lung-Resident Memory Th2 Cells in Asthma

NCT03455959
View directory record Official record
Conditions
Asthma, Allergic
Interventions
Bronchoscopy/BAL, Airway Brushing
Procedure
Lead sponsor
Andrew D. Luster, M.D.,Ph.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Phase 2 Interventional

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW873140, Kaletra (lopinavir/ritonavir)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00098774
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cytarabine, etoposide, leucovorin calcium, methotrexate, temozolomide
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
30
States / cities
San Francisco, California • Lewes, Delaware • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care

NCT05925374
View directory record Official record
Conditions
Social Stigma, Substance Use Disorders, HIV Infections, Physician-Patient Relations
Interventions
Substance use stigma training
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Talking Card for Asthma

NCT02041013
View directory record Official record
Conditions
Asthma
Interventions
Taking Card
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
4 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Tampa, Florida • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Zostavax in Systemic Lupus Erythematosus

NCT01474720
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Zostavax vaccine
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Early Phase 1 Interventional

Raltegravir for HAM/TSP

NCT01867320
View directory record Official record
Conditions
HTLV-I Infection
Interventions
Raltegravir
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Nutritional Assessment Intervention to Improve Cancer-Related Fatigue

NCT00507260
View directory record Official record
Conditions
Leukemia, Lymphoma, Fatigue
Interventions
Food Record, Nutritional Consults
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Not applicable Interventional

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02967380
View directory record Official record
Conditions
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine
Procedure · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

NCT00845676
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus, HIV Infections
Interventions
Pegylated interferon alfa-2a + Ribavirin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 30, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Allergens in Inner-City Schools and Childhood Asthma

NCT01756391
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 15 Years
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)

NCT01227590
View directory record Official record
Conditions
Drug Interactions, Human Immunodeficiency Virus
Interventions
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated Phase 1 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

NCT00003613
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions
O6-benzylguanine, carmustine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Adoptive Transfer of Haploidentical NK Cells and N-803

NCT03899480
View directory record Official record
Conditions
Hiv, HIV Infections, Immune Deficiency
Interventions
Haploidentical Natural Killer (NK) Cells
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

NCT00001688
View directory record Official record
Conditions
HIV Infection
Interventions
Ritonavir, Nevirapine, Stavudine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 1:40 PM EDT
Completed No phase listed Observational

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

NCT02716103
View directory record Official record
Conditions
Amyloidosis
Interventions
blood collection, bone marrow collection
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Not yet recruiting Phase 1 Interventional

huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers

NCT07891468
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation
Interventions
huCART19-IL18-CD428z cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 30, 2026, 1:40 PM EDT
Terminated No phase listed Observational

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

NCT02316691
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 1:40 PM EDT